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Abstract
Background: The epidemiology of fevers and their management in areas of low malaria transmission in Africa is
not well understood. The characteristics of fever, its treatment and association with infection prevalence from a
national household sample survey in the northern states of Sudan, an area that represents historically low parasite
prevalence, are examined in this study.
Methods: In October-November 2009, a cluster sample cross-sectional household malaria indicator survey was
undertaken in the 15 northern states of the Sudan. Data on household assets and individual level information on
age, sex, whether the individual had a fever in the last 14 days and on the day of survey, actions taken to treat the
fever including diagnostic services and drugs used and their sources were collected. Consenting household
members were asked to provide a finger-prick blood sample and examined for malaria parasitaemia using a rapid
diagnostic test (RDT). All proportions and odds ratios were weighted and adjusted for clustering.
Results: Of 26,471 respondents 19% (n = 5,299) reported a history of fever within the last two weeks prior to the
survey and 8% had fever on the day of the survey. Only 39% (n = 2,035) of individuals with fever in last two weeks
took any action, of which 43% (n = 875) were treated with anti-malarials. About 44% (n = 382) of malaria
treatments were done using the nationally recommended first-line therapy artesunate+sulphadoxine-
pryrimethamine (AS+SP) and 13% (n = 122) with non-recommended chloroquine or SP. Importantly 33.9% (n =
296) of all malaria treatments included artemether monotherapy, which is internationally banned for the treatment
of uncomplicated malaria. About 53% of fevers had some form of parasitological diagnosis before treatment. On
the day of survey, 21,988 individuals provided a finger-prick blood sample and only 1.8% were found positive for
Plasmodium falciparum. Infection prevalence was higher among individuals who had fever in the last two weeks
(OR = 3.4; 95%CI = 2.6 - 4.4, p < 0.001) or reported fever on the day of survey (OR = 6.2; 95%CI = 4.4 - 8.7, p <
0.001) compared to those without a history of fever.
Conclusion: Across the northern states of the Sudan, the period prevalence of fever is low. The proportion of
fevers that are likely to be malaria is very low. Consequently, parasitological diagnosis of all fevers before treatment
is an appropriate strategy for malaria case-management. Improved regulation and supervision of health workers is
required to increase the use of diagnostics and remove the practice of prescribing artemisinin monotherapy.
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The diagnosis and treatment of fevers in Africa is
undergoing a paradigm shift, away from the widely pro-
moted concept that all fevers should be regarded as
malaria [1-6] to more informed guidelines that promote
the use of parasitological diagnostics and a rational use
of artemisinin-based combination therapies [7]. This
migration from presumptive to parasitological confirmed
diagnosis is for a combination of reasons: the costs of
replacement therapies for failed monotherapy [8], the
recognition that parts of Africa are undergoing an epi-
demiological transition that supports Plasmodium falci-
parum transmission intensities considerably lower than
ten years previously with a natural consequence that
most fevers are not associated with malaria infection
[9-11] and a more general ambition to improve the
standards and quality of malaria case-management and
its corollary that non-malaria febrile conditions receive
better investigation, intervention and prognosis, and the
advent of rapid diagnostic tests [7,12-15].
However, the understanding of the epidemiology of
fevers and their management in areas where parasite
exposure is infrequent is limited. Research into the epi-
demiology of malaria and understanding the impacts of
control and disease management have traditionally
focused on stable, high transmission areas of Africa.
This study investigates the characteristics of fever man-
agement and infection prevalence from a national
household survey in the northern states of Sudan, an
area of historically low malaria risk.
Methods
Malaria in the northern states of Sudan
Over 27 million people live in the 15 northern states of
Sudan with the National Malaria Control Programme
based in Khartoum responsible for the implementation
of federal policies and guidelines for malaria control.
Stable, malaria transmission to both P. falciparum and
Plasmodium vivax has historically been constrained by
the arid climate among the most northern states
that border Egypt [16-18]. In 2007, it was estimated that
5.7 million people were exposed to stable falciparum
and to limited vivax malaria transmission in the north-
ern states of Sudan [19,20], with a highly over-distribu-
ted pattern of risk that was generally characterized by
low parasite prevalence [19,21]. In 2005, a household
sample survey reported an overall P. falciparum infec-
tion prevalence of 3.7% among all age groups using
microscopy and a 14-day period prevalence of self-
reported fever of 37% in eight northern states [21].
Despite the low prevalence of malaria infection it has
been estimated that over 50% of all fevers are managed
as malaria [22,23]. By 2006, malaria was thought to con-
tribute to 50% of all out-patient diagnoses reported as
part of the Health Information System of the northern
states of the Sudan and accounted for an estimated
44,000 deaths in 2002 [18].
Against a background of escalating chloroquine resis-
tant P. falciparum [24,25], northern states of the Sudan
changed their treatment policy to artemisinin-based
combination therapy (ACT) in June 2004 [26]. The cur-
rent standard treatment protocol for uncomplicated fal-
ciparum malaria is artesunate plus sulphadoxine/
pyrimethamine (AS+SP), as first-line and artemether-
lumefantrine (AL) as second-line of treatment [23,27].
Overseas development assistance to support scaling up
of malaria control activities rose sharply in 2004 with
support from the Global Fund for AIDS, TB and
Malaria (GFATM) approved malaria funding and by
2009 approximately $33 million had been disbursed by
the GFATM [28] to support malaria activities across the
northern states of the Sudan. Since 2005, the Sudan
national malaria control programme (NMCP) has dis-
tributed over 6 million long-lasting insecticide treated
nets, expanded residual insecticide spraying of houses in
selected areas; and supported the improvement of
malaria case-management through in-service training of
health workers in revised standard treatment guidelines
and increased use of diagnostics and improving the sup-
ply of AS+SP to over 90% of government health
facilities.
Household malaria survey
A household sample survey of basic malaria coverage
indicators was undertaken between October and
November 2009 across the northern 15 states of Sudan.
A sample of 6,000 households across 300 clusters was
selected using a multi-stage probability proportional to
size (PPS) cluster sample design. The number of house-
holds required was determined using the Roll Back
Malaria Monitoring and Evaluation Reference Group for
indicators in young children (RBM-MERG) approach
[29] with survey powered to detect changes in the pro-
portion of children under the age of five years sleeping
under an ITN with precision at the national and state
levels. As a compromise between precision and logistics,
an average of 20 households per clusters was used to
estimate the number of sampling units to survey. To
identify the location of the clusters to be surveyed a list
of Popular Administrative Units (PAUs) from the
National Statistics and Census Office (NSCO) was used
to determine the PAUs in which survey clusters would
be located. The PAUs in each state were selected
according to PPS method distributed proportionately
into urban and rural within each state as defined during
the 2008 national census. The list and size of all enu-
meration areas (EAs) within the selected PAU was then
assembled by the NSCO and a further sampling to
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using the PPS method separately for urban and rural.
Within each cluster, 20 households were randomly
selected and all members of the households visited at
the time of survey were interviewed using the relevant
survey questionnaire.
A community sensitization exercise was undertaken a
few weeks before and throughout the survey period in
the print, radio and television media by the NMCP of
the Federal Ministry of Health. Thirty coordinators
selected at national and state levels were trained to be
in-charge of the day-to-day management of the survey
in their respective states. A total of 196 field team mem-
bers (28 teams) were trained on general interviewing
skills, administration of consent forms, filling of ques-
tionnaires, collection of blood samples, and appropriate
treatment of individuals found positive for malaria. The
team members were also trained in the use of global
positioning systems for mapping of clusters. Each of the
28 survey teams, consisting of seven persons (one super-
visor; two interviewers; two nurses or equivalent; and
two laboratory technicians) visited one cluster per day.
A household members’ questionnaire was adapted
from the standard RBM-MERG tools [29] to ensure
information was collected from all age groups. The
questionnaire was developed first in English and trans-
lated into Arabic and draft versions were checked and
piloted independently by members of the survey teams
conversant in both languages to reduce ambiguities in
translation. This questionnaire captured information on
each usual and visiting resident member at household
during the survey. Information including: age, sex, edu-
cational status, relationship to the head of the house-
hold, use of mosquito nets and insecticide-treated nets
(ITN) the night prior to the survey, whether the room
slept in last night had been subject to residual spraying
in the last 12 months, and whether the individual had
had a fever in the last 14 days were captured. Additional
information was collected on whether the fever was pre-
sent on the day of the survey, actions taken to treat the
fever including diagnostic services used, drugs used and
their sources. At the end of each interview each house-
hold member was asked to provide a finger prick blood
sample following informed consent and examined for
malaria parasitaemia using an RDT (First Response
Malaria Ag (pLDH/HRP2) COMBO, Premier Medical
Corporation Ltd). The test gave results on whether
infection was due to P. falciparum or mixed species but
did not distinguish between P. falciparum and P. vivax.
At the end of each survey day, all questionnaires and
RDTs were submitted to the state coordinators for
review and storage. The state coordinators reviewed the
survey team’s daily submissions and suggested correc-
tions where necessary.
Data entry and analysis
Twenty trained data entry personnel were hired to capture
information from the survey questionnaires using custo-
mized data entry screens developed in Microsoft Access
2007. Once entered, data were checked for consistencies
by a data manager and correctable errors reconciled.
Reports of fever were classified into two categories;
those who reported to have had a fever in the last two
weeks preceding the survey and those who reported fever
present on the survey day. Treatment actions and drug
classes were classified as first actions only. Common
across all malaria indicator surveys, discerning multiple
treatment sources, their sequence and timing has proved
complex and difficult to interpret. Where surveys have
investigated multiple treatment actions the first action is
usually the dominant reported action and second or third
actions are relatively rarely reported [30,31]. Descriptive
analysis of fever and infection prevalence was undertaken
according to age, sex, rural-urban residence, use of ITN
and wealth quintile. All data were analyzed using STATA
version 11.0 (StatCorp, College Station, Texas). All pro-
portions and odds ratios were weighted and adjusted for
clustering using the svy: command in STATA. Because the
selection of the PAUs and the clusters was done probabil-
ity proportional to size, sample weighting was implemen-
ted only at the household level and weights were derived
as the inverse of the probability of selecting a household
within a cluster. Multivariate regression models were fitted
using the svy: logistic command allowing for clustering and
weighting of the data to assess the association of fever as a
risk factor for malaria infection. The analysis controlled
this association for age, residence, use of ITN, and wealth
quintile. For each predictor the Odds Ratio (OR), 95%
confidence interval (CI), and P-values were recorded.
Ethical considerations
Ethical clearance was provided by the National Research
Ethics Committee of the Federal Ministry of Health
(fmoh/rd/SEC/09, date: 7/9/2009). All household mem-
bers and parents/guardians fo children were informed
about all relevant aspects of the study including its aim,
procedures, potential risk and hazards. A signed
informed consent was obtained and assurance given that
the participation in the study was strictly voluntary and
all information would remain confidential and anon-
ymized. Persons who volunteered a blood sample for
RDT malaria testing and were found positive were trea-
ted immediately by survey nurses using nationally
recommended AS+SP age-defined dosage.
Results
Survey characteristics
A total of 5,980 of 6,000 sampled households were sur-
veyed from 300 clusters. 26,471 individuals from the
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survey. 55.7% of surveyed individuals were female, 19.4%
were children under five years of age and 64.3% were
from rural areas. About 83% (n = 21,988) of the indivi-
duals provided a finger prick blood sample for testing
malaria parasites while the rest refused to provide blood
samples following informed consent and requests for
voluntary participation.
Epidemiological features of reported fever and infection
prevalence
Among all surveyed individuals, 19% reported a history
of fever in the last two weeks preceding the survey date
and 8% were febrile on the day of survey (Table 1, Addi-
tional File 1). There were very small differences with
age, however female and rural residents had higher fever
prevalence (in the last two weeks or on the day of
survey) compared to male and urban residents respec-
tively (Table 1). Fever prevalence was more than two
times higher among individuals from the poorest house-
hold compared to those from the least poor households.
Among the 21,988 individuals who volunteered a blood
sample for RDT examination for the presence of malaria
infection only 1.8% were found positive (Table 2, Addi-
tional File 1). It is assumed that the majority of these
infections were P. falciparum however it is not possible
to disaggregate vivax or other Plasmodium infections
from the reported positive cases. There was minimal age
pattern in infection prevalence (Table 2). The prevalence
of infection was higher in rural areas (2.4%) compared
to urban residents (0.8%); among those who did not use
nets (2.4%) compared to those who did (1.6%) and
among individuals from the poorest households (2.7%)
compared to the least poor (2.7%). Importantly, the
Table 1 Prevalence of fever in last two weeks, on the day of survey and treatment seeking (N = 26,471) and malaria
infection tested using rapid diagnostic tests (N = 21,988) by gender, age, residence, used of insecticide treated nets
(ITN) and wealth quintile
Number of
persons
interviewed
Fever Malaria infection
Fever last 2 weeks %
(95% CI) (n/N = 5,299/
26471)
Fever on survey day %
(95% CI) (n/N = 2,370/
2,6471)
Fevers for which treatment
was sought (n/N = 2,035/
5,299)
Positive % (95% CI)
(n/N = 489/21,988)
*2
Gender
Male 11,720 16.8 (15.6-17.9) 7.3 (6.4-8.1) 42.6 (39.2-46.0) 2.1 (1.6-2.7)
Female 14,751 20.9 (19.6-22.2) 9.1 (8.3-10.0) 36.7 (34.2-39.2) 1.5 (1.1-2.0
*
1Age
<1 1,148 20.7 (18.3-23.3) 11.0 (8.9-13.2) 45.2 (37.7-52.6) 2.1 (1.1-3.2)
1-4 3,982 23.3 (21.3-25.3) 7.8 (6.6-9.0) 44.2 (40.1-48.2) 2.0 (1.2-2.9)
5-9 4,145 15.9 (14.3-17.5) 7.1 (6.0-8.2) 40.2 (35.0-45.3) 3.0 (2.0-4.0)
10-19 5,432 14.5 (13.1-15.8) 5.9 (5.0-6.9) 37.0 (32.6-41.4) 2.1 (1.4-2.8)
>19 11,764 20.6 (19.4-21.8) 9.7 (8.9-10.6) 37.0 (34.4-39.6) 1.1(0.8-1.4)
Residence
Urban 9459 16.1 (14.3-17.9) 6.9 (5.6-8.2) 46.1 (42.6-49.6) 0.8 (0.5-1.1)
Rural 17,012 21.2 (19.5-22.9) 9.4 (8.3-10.5) 35.0 (31.7-38.2) 2.4 (1.7-3.2)
Use of
ITN
No 23,377 18.6 (17.5-19.8) 7.9 (7.2-8.7) 38.9 (36.3-41.6) 2.4 (1.2-3.6)
Yes 3,094 22.2 (20.0-24.5) 11.1 (9.2-13.1) 39.5 (34.7-44.4) 1.6 (1.2-2.1)
Wealth
quintile
Least Poor 5,649 13.6 (12.0-15.3) 4.3 (3.3-5.2) 53.0 (48.6-57.4) 0.4 (0.2-0.7)
Second 5,776 14.9 (13.3-16.4) 5.9 (4.8-7.1) 44.2 (39.5-48.9) 1.1 (0.7-1.6)
Third 5,183 21.4 (19.2-23.7) 9.9 (8.3-11.6) 40.6 (36.4-44.8) 1.9 (1.1-2.6)
Fourth 5,006 22.3 (20.0-24.8) 10.9 (9.2-12.7) 34.5 (30.4-38.5) 3.3 (1.7-4.9)
Most Poor 4,857 26.4 (23.3-29.5) 12.8 (10.8-14.7) 27.2 (22.8-31.6) 2.7 (1.5-4.0)
Total 26,471 19.1 (17.9-20.2) 8.3 (7.6-9.1) 39.1 (36.6-41.5) 1.8 (1.3-2.2)
Proportions are weighted and cluster adjusted.
*
1 67 individuals did not have age data.
*2 Of the 4,483 individuals who did not provide finger-prick sample for malaria testing, 51% were urban, 52% were male, with refusal highest in Khartoum state
at 25%.
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gender, age, residence, use of ITN and wealth quintile,
individuals who reported fever in the last two weeks and
on the day of survey were three times (Odds Ratio (95%
confidence interval) 3.4 (2.6-4.4)) and 6 times (OR (95%
CI) 6.2 (4.4-8.7)) more likely to have malaria infection
(Table 2). Interestingly, use of ITN was not significantly
associated with the likelihood of having malaria
infection.
Treatment actions for fever, access to diagnostic facilities
and associations with infection prevalence
Among the 5,299 self-reported fevers occurring during
the 14 days prior to the survey 39% (n = 2,035) had
some treatment action (Table 1). Treatment seeking was
higher among female, children, urban residents and
those from the least poor households. Among those
who sought treatment, 95% were treated with ‘Western-
type’ drugs, 43% were treated with anti-malarials while
the remaining 57% were treated with other drugs,
mainly antipyretics (Table 3, Additional File 1). Almost
53% of those febrile individuals who sought treatment
were tested (Table 3) with testing rates higher among
urban residents (70%) compared to rural (42%). Majority
of treatments and tests were undertaken in government
health facilities, mainly health centres and hospitals and
only about 22% of all treatments were in the private sec-
tor. Among the 875 individuals who were treated for
malaria, 44% were treated with the nationally recom-
mended first-line therapy for uncomplicated malaria, AS
+SP with 87% of these treatments occurring in the gov-
ernment sector (Table 4, Additional File 1). Chloroquine
or SP, monotherapies not recommended for the man-
agement of malaria in the northern states of Sudan,
were used to treat 13% of all malaria cases and quinine
was reportedly administered for 5.0% (Table 4). Impor-
tantly 34% of all malaria treatments were reportedly
managed using injectable artemether monotherapy
which was more frequently obtained from public sector
facilities, notably from higher order facilities such as
hospitals and health centres (Table 4).
Of those individuals who reported a fever episode in
the last two weeks and took action 40% took action
within 24 hours and 67% within 48% hours. Of those
that were treated within 24/48 hours about 22% were
treated with AS+SP, 16.1% with artemether, 2% with
quinine, 5% with SP or CQ and about 55% with anti-
pyretics and other non-anti-malarial drugs.
Discussion
Infection prevalence, as judged by RDT positivity rates,
among 21,988 people sampled across 300 communities
of the 15 northern states Sudan was very low, 1.8%.
These results have not been corrected using polymerase
chain reaction detection, to account for the documented
false positive rates [13,32] and it is possible that the true
prevalence between October and November 2009 is
lower. The prevalence documented across eight north-
ern states in 2005 using microscopy was 3.7% and it is
possible that prevalence might be declining in the north-
ern states of Sudan. However, such comparisons should
be made with caution because of the acutely seasonal
nature of transmission in semi-arid areas and the limita-
tions of point-estimates of transmission in such areas.
Nevertheless against a background of low malaria infec-
tion risk, nearly one in five people reported a febrile
event during the two-week period prior to the survey. It
is not clear what the majority of these events represent
Table 2 Results of multivariate regression analysis of the
association of fever with malaria when controlled for
gender, age, residence, use of insecticide treated nets
(ITN) and wealth quintile
Fever two weeks
included: Odds Ratio
(95% CI), p-value
Fever on the day of survey
included: Odds Ratio (95%
CI), p-value
Fever in
the last
two weeks
No Ref. -
Yes 3.4 (2.6-4.4), <0.001 -
Fever on
the day of
survey
No - Ref.
Yes - 6.2 (4.4-8.7), <0.001
Gender
Male Ref. Ref.
Female 0.7 (0.6-0.9), 0.013 0.7 (0.6-0.9), 0.017
*
1Age
<1 Ref. Ref.
1-4 1.0 (0.5-1.8), 0.935 1.1 (0.6-2.1), 0.723
5-9 1.7 (0.9-3.1), 0.074 1.8 (0.9-3.1), 0.054
10-19 1.4 (0.8-2.7), 0.255 1.6 (0.8-2.9), 0.173
>19 0.6 (0.4-1.2), 0.150 0.7 (0.4-1.2), 0.143
Residence
Urban Ref. Ref.
Rural 1.7 (1.1-2.9), 0.037 1.9 (1.1-3.2), 0.022
Use of ITN
No Ref. Ref.
Yes 1.4 (0.8-2.2), 0.201 1.4 (0.8-2.2), 0.221
Wealth
quintile
Least Poor Ref. Ref.
Second 2.2 (1.2-4.1), 0.015 2.0 (1.1 -3.8), 0.031
Third 3.0 (1.6-5.7), 0.001 2.7 (1.4-5.1), 0.003
Fourth 4.6 (2.3-9.5), <0.001 4.0 (1.9-8.5), <0.001
Most Poor 3.4 (1.6-7.5), <0.002 2.9 (1.4-6.5), 0.007
*
1 14 individuals did not have age data; Ref. = reference.
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rile people do not seek any treatment and are apparently
well during the survey interview. However 40% did seek
treatment and almost half of these treatment actions
included the use of anti-malarials. The prevalence of
“malaria” treatment is higher than a point prevalence of
infection and may suggest a degree of over-treatment.
However, it is also important to note that the prevalence
of infection is over six-times higher (OR = 6.2; Table 2)
among patients with a fever on the day of the survey
and in an area where transmission intensity is low and
the acquisition of functional clinical immunity to new
infections is low [33], infection may be more directly
related to symptoms, as such the prevalence of fever
and infection is closer to the reported anti-malarial use
recorded during this survey. Clearly this presumes that
those fevers that don’t seek treatment are not associated
with malaria and those who seek treatment are appro-
priately defined as malaria. Neither of these caveats can
be tested directly through cross-sectional surveys.
When treatment for fevers was sought, over 70% of
patients were managed at the Government’sh e a l t h
Table 3 Type of treatment and prevalence parasitological diagnosis before treatment by source among individuals
who reported having fever in last two weeks and who took action (N = 2,035)
Use of any drug, %
(95% CI) (n/N = 1,935/
2,035)
Use of anti-malarials, %
(95% CI) (n/N = 875/
2,025)
Use of other drugs, %
(95% CI) (n/N = 1,060/
2,035)
Parasitologically tested for malaria before
any treatment, % (95% CI) (n = 1,015/
2,035)*
Overall 95.4 (94.4-96.4) 42.6 (39.2-46.0) 57.4 (54.0-60.8) 52.8 (48.6-57.0)
By treatment source
Government
Hospital 29.0 (25.1-32.9) 28.2 (23.1-33.4) 29.6 (25.4-33.7) 38.8 (33.1-44.6)
Health centre 30.3 (26.4-34.3) 33.7 (28.2-39.2) 27.7 (23.7-31.7) 36.9 (31.4-42.4)
Basic health unit 11.4 (8.1-14.5) 11.4 (7.4-15.5) 11.3 (8.1-14.6) 4.6 (2.8-6.2)
Community
Health Worker
6.9 (4.5-9.3) 5.9 (3.2-8.6) 7.7 (4.9-10.6) 3.4 (1.9-5.0)
Private
Health facility/
pharmacy/drug
Store
15.3 (12.8-17.7) 16.0 (12.3-19.7) 14.7 (12.0-17.5) 15.2 (11.6-18.9)
Shop 5.5 (4.0-6.9) 3.8 (2.2-5.3) 6.8 (4.8-8.8) 0.4 (0.0-0.9)
Other 1.6 (0.9-2.3) 9.5 (0.2-1.7) 2.2 (1.0-3.3) 0.5 (0.0-1.1)
Proportions are weighted and cluster adjusted.
*Individuals tested for malaria when reporting at a health facility with fever. 57% of these received anti-malarials compared to 29% of those who were not
tested. It was not possible to discern whether only the positive cases were treated with anti-malarials because of problems with recall and incompleteness of test
status.
Table 4 Type of anti-malarials used by source among individuals who reported having fever in last two weeks and
who were treated for malaria (N = 875).
Anti-malarial type
AS+SP (n =
382)
SP or Chloroquine (n =
122)
Quinine (n =
39)
Artemether (n =
296)
Other
† (n =
36)
Overall 43.9 (39.6-48.2) 13.4 (10.6-16.2) 4.5 (2.8-6.1) 33.7 (30.0-37.4) 4.6(2.7-6.5)
By treatment source
Government
Hospital 29.0 (21.2-36.8) 20.3 (11.3-29.3) 50.2 (27.8-72.6) 28.4 (21.4-35.3) 21.4 (7.6-35.1)
Health centre 36.5 (27.3-45.7) 24.0 (14.7-33.2) 33.6 (11.1-56.1) 35.8 (29.2-42.4) 20.2 (4.7-35.8)
Basic health unit 10.5 (4.9-16.0) 14.6 (6.6-22.7) 5.4 (-0.0-11.1) 13.7 (7.6-19.7)
Community Health Worker 7.0 (2.1-11.8) 5.8 (0.7-11.0) 7.2 (-0.2-14.6) 4.4 (1.7-7.2) 5.5 (-5.0-15.9)
Private
Health facility/pharmacy/drug
Store
14.6 (9.3-20.0) 20.0 (10.9-29.1) 2.1 (-1.9-6.2) 14.7 (10.3-19.1) 40.2 (18.3-62.1)
Shop 1.6 (0.3-28.6) 15.2 (7.3-23.2) 1.4 (-1.4-4.2) 1.1 (-0.6-2.9) 12.7 (-4.3-29.9)
Other 0.7 (-0.0-1.7) 1.8 (-0.0-3.8)
Proportions are weighted and cluster adjusted.
†13 individuals took AL, 23 took unspecified anti-malarial drugs.
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The use of the private retail sector in the northern
states of Sudan is not as prolific as described in many
other African settings [34]. Partly as a consequence of
the high government sector use, the most striking obser-
vation was the wide-spread reported access to parasito-
logical diagnosis among febrile respondents who sought
treatment (53%; Table 3). Strengthened laboratory sup-
port for malaria diagnosis has been an important part of
the recent malaria case-management strategy [23]. It
was not possible to stratify analysis on the reported test
results as these data were incomplete and were not veri-
fied against patient or care-giver notes to distinguish
true test positive results from the results told to the
patients. However, what is clear is that parasitological
testing per se did influence the prescriptions made and a
higher proportion of tested patients received the nation-
ally recommended first-line treatment compared for
uncomplicated malaria to those not tested for malaria
(data not shown). Separate studies are underway to
examine the quality of care and prescription practices
among health workers in the government health sector
to investigate prescribers’ adherence to parasitological
test results and the associated prescriptions. The inter-
national milestones for successful implementation of
case-management are currently anchored around 60%,
80% or universal treatment of all fevers with anti-malar-
ial drugs within 24/48 hours [35-37]. The Sudan
National Malaria Strategy for the northern states outlines
the ambition that by 2012 “80% of malaria patients will
receive prompt and effective treatment” [23]. In addition
the current national malaria strategy aims at reaching
100% laboratory confirmation of reported malaria inci-
dence by 2010 [23]. A more adequate target for Sudan and
many countries in Africa is that all fevers are tested for
malaria and all those reported as positive for malaria infec-
tion are treated with national first-line recommended ther-
apy. That only 19% of fevers (and 45% of those who were
treated with anti-malarials) were treated with nationally
recommended AS+SP and that only 14% were managed
with AS+SP within 48 hours is not a failure to reach estab-
lished milestones as most fevers are not malaria and thus
should not be held to account as a failure. Indeed it could
be argued that the fewer fever/anti-malarial drug expo-
sures the greater the success of programmes promoting
effective diagnostic strategies.
Of greatest concern was the reported use of artemether,
available in injectable forms at Government clinics, despite
an international ban on its use to manage uncomplicated
malaria by the World Health Organization in 2006 [38].
The use of artemether in Sudan has been attributed to a
belief by some prescribers and patients that injections
have a stronger effect and work faster than oral medica-
tions and that there may be patient pressure to use these
medicines [39,40]. Furthermore parasitological diagnosis
of malaria was a predictor of artemether use, where
patients were almost 3 times more likely to receive this
drug if tested compared to if no parasitological test was
done (data not shown). Chloroquine and SP continue to
be available at government clinics and are prescribed,
more frequently if no parasitological diagnosis is
attempted than when malaria testing is performed, despite
the reported wide-spread resistance across Sudan to both
these mono-therapies [22,41,42]. Non-adherence to
national standard treatment guidelines at the point of care
is common across many settings in Africa [43-47], pre-
viously reported in Sudan [48] and their reasons and
determinants complex [45,49]. Exploring the prescription
practices and patient treatment actions demands a more
rigorous combination of facility and community-based
qualitative and quantitative investigations than was possi-
b l et h r o u g ht h el a r g e - s c a l es i n g l ec r o s s - s e c t i o n a ls a m p l e
survey described here.
About 67% of fevers that sought treatment in the cur-
rent study were treated after 48 hours of onset of symp-
toms. Similar findings have been reported in Sudan where
40% of the fever cases sought treatment after 72 hours of
onset of symptoms and a mean delay of 67.8 hours before
attending a health facility [22,50]. Lack of money, waiting
for improvement, low coverage with health facilities, dissa-
tisfaction with services, difficulty to reach the facilities
especially during rainy season, and waiting for the effect of
traditional remedies have been highlighted as some of the
reasons for delayed treatment [26,51].
Conclusions
This study demonstrates that fever prevalence in the
Sudan is low and with a P. falciparum infection preva-
lence of only 1.8%, the proportion of fevers attributable
to malaria would also be extremely low. Consequently,
parasitological diagnosis of malaria at all levels of the
health system must become part of the malaria case
management policy. Although the current testing rate of
fevers of 53% is higher than those of most African coun-
tries, it still remains low largely because microscopy in
the Sudan is limited to hospitals and health centres [52]
and RDTs have not been scaled up nationally. Ongoing
revision of the national malaria strategy aims to commit
the northern states of the Sudan to parasitological diag-
nosis of all fevers which will be supported with rapid
scale-up of RDTs in the all public health facilities, which
provide almost 80% of all fever treatments [Abdalla, Per-
sonal Communication]. Concerns remain, however, on
the types of anti-malarials used for the treatment of
fevers with both chloroquine and SP still in circulation,
both of which have failed in the northern states of
Sudan in the treatment of P. falciparum infections,
although chloroquine is still used for the treatment of
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Page 7 of 9P. vivax malaria in the country. Importantly, Sudan
must urgently focus attention on stopping the wide-
spread use of artemether for fever treatment, a mono-
therapy banned internationally by the World Health
Organization for treatment of uncomplicated malaria, to
avoid the emergence of resistance of artemisinin which
could lead to devastating consequences both in the
Sudan and the rest of Africa. Interestingly, majority of
patients who received artemether have obtained this
drug from the public health sector and an investigation
of the reasons behind this practice, given that the health
workers from this sector have had extensive training in
malaria case-management, should be undertaken.
Additional material
Additional file 1: A summary of numerators (n) and denominators
(N) for Tables 1, 3 and 4 in the main text The additional file presents
the numbers of persons: interviewed during the 2009 national malaria
indicator survey in the northern states of Sudan; with fever in the last
two weeks and on the day of survey; sought treatment for fever; tested
for malaria; positive for malaria; used drugs; used antimalarials; and by
type of antimalarial.
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